Wedbush restated their outperform rating on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) in a report issued on Wednesday morning, Benzinga reports. The firm currently has a $11.00 price objective on the stock. Wedbush also issued estimates for Monte Rosa Therapeutics’ Q2 2024 earnings at ($0.37) EPS, Q3 2024 earnings at ($0.34) EPS, […]
Monte Rosa Therapeutics (NASDAQ:GLUE) Now Covered by Analysts at Wedbush theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Equities researchers at Wedbush initiated coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research note issued on Thursday, Briefing.com reports. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 131.09% from the company’s previous close. […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 2,360,000 shares, a decrease of 20.5% from the November 30th total of 2,970,000 shares. Currently, 7.5% of the company’s stock are sold short. Based on […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the target of a large increase in short interest in July. As of July 31st, there was short interest totalling 2,800,000 shares, an increase of 6.5% from the July 15th total of 2,630,000 shares. Currently, 7.0% of the company’s stock are sold short. Based on […]